Evidence map›Paper›PMID 29054930›Full record

ArticleThe Journal of biological chemistry2017

The transcription factor MEF2A fine-tunes gene expression in the atrial and ventricular chambers of the adult heart.

Jose L Medrano, Francisco J Naya

Open access · hybridAbstract readValidation Study
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Histone Deacetylase 7 protects against pathologic cardiac hypertrophy.Journal of molecular and cellular cardiology · 2026
    Article
  2. NADCommunications biology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. FoxP1 Represses MEF2A in Striated Muscle.Molecular and cellular biology · 2024
    Article
  8. Effect of BovineGenes · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. The genetics of human performance.Nature reviews. Genetics · 2022
    Review
  14. Article
  15. Frontiers in cell and developmental biology · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jose L MedranoFrom the Department of Biology, Program in Cell and Molecular Biology, Boston University, Boston, Massachusetts 02215.
Francisco J NayaFrom the Department of Biology, Program in Cell and Molecular Biology, Boston University, Boston, Massachusetts 02215 fnaya@bu.edu.
Boston University · US

Funding

Boston University Clinical and Translational Science Institute - U ProgramU54TR001012 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CENTER, DAVID M. · 2014 to 2014
$3.9M
MEF2 Function in Cardiac Muscle DevelopmentR01HL073304 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI NAYA, FRANCISCO J · 2003 to 2013
$3.3M
NCATS NIH HHS U54 TR001012NHLBI NIH HHS R01 HL073304
6 · The paper itself

Abstract

The distinct morphological and functional properties of the cardiac chambers arise from an elaborate developmental program involving cell lineage determination, morphogenesis, and dynamic spatiotemporal gene expression patterns. Although a number of transcription factors have been identified for proper gene regulation in the chambers, the complete transcriptional network that controls these patterns remains poorly defined. Previous studies have implicated the MEF2C transcription factor in the regulation of chamber-restricted enhancers. To better understand the mechanisms of MEF2-mediated regional gene regulation in the heart, we took advantage of MEF2A knock-out (KO) mice, a model that displays a predominantly ventricular chamber phenotype. Transcriptomic analysis of atrial and ventricular tissue from adult MEF2A KO hearts revealed a striking difference in chamber gene expression, with a larger proportion of dysregulated genes in the atrial chambers. Canonical pathway analysis of genes preferentially dysregulated in the atria and ventricles revealed distinct MEF2A-dependent cellular processes in each cardiac chamber. In the atria, MEF2A regulated genes involved in fibrosis and adhesion, whereas in the ventricles, it controlled inflammation and endocytosis. Finally, analysis of transcription factor-binding site motifs of differentially dysregulated genes uncovered distinct MEF2A co-regulators for the atrial and ventricular gene sets, and a subset of these was found to cooperate with MEF2A. In conclusion, our results suggest a mechanism in which MEF2 transcriptional activity is differentially recruited to fine-tune gene expression levels in each cardiac chamber. This regulatory mechanism ensures optimal output of these gene products for proper physiological function of the atrial and ventricular chambers.

Indexed as

AnimalsGene Expression RegulationHeart AtriaHeart Defects, CongenitalHeart VentriclesMEF2 Transcription FactorsMiceMice, 129 StrainMice, Inbred C57BLMice, KnockoutTissue DistributionMef2a protein, mouseMEF2 Transcription Factorscardiac developmentgene knockoutgene regulationmousetranscription factortranscriptomics

Identifiers

PMID29054930
PMCPMC5743072
OpenAlexW2765237779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.